OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.
CurrentCurativePolicy CHP-IP-2026-098
Brain Metastases With Cerebral Edema
Customize your policy alerts
Sign up for curative Policy CHP-IP-2026-098 alerts
Get alerted when Policy CHP-IP-2026-098 changes without checking for updates manually.
Monitor payer policy activity
Receive email alerts as soon as relevant payer policies are published or updated.
Governs acute inpatient admission, level-of-care assignment, continued stay, and discharge for adult members with brain or leptomeningeal metastases complicated by symptomatic edema or related neurologic complications under Curative commercial PPO and EPO plans.
Policy Summary
PayerCurative
PolicyBrain Metastases With Cerebral Edema
Policy CodePolicy CHP-IP-2026-098
Change TypeNo material change
Effective DateN/A
Next Review DateN/A
Key ActionProvide serial neurologic examinations, including GCS and focal neurologic deficits.
There is a new, recurrent seizure (2 or more in 24 hours), prolonged seizure lasting 5 minutes or longer, or any seizure without return to neurologic baseline.
There are signs of raised intracranial pressure, including persistent vomiting with headache, papilledema, or a Cushing response.
Leptomeningeal disease is accompanied by hydrocephalus, cranial neuropathies, or declining consciousness.
At least one hospital-level service required
IV corticosteroids, including dexamethasone, are required with neurologic checks every 1 to 4 hours.
Hyperosmolar therapy with mannitol or hypertonic saline is required with serum sodium or osmolality checks every 4 to 6 hours.
IV antiseizure medication loading or titration is required after a seizure cluster or status epilepticus.
Neurosurgical intervention is planned within 72 hours, including resection, biopsy, external ventricular drain, ventriculoperitoneal shunt, or Ommaya reservoir.
Urgent radiation is started within 24 to 72 hours because progressive neurologic decline makes outpatient travel unsafe.
Observation or outpatient instead of inpatient
Observation for up to 24 to 48 hours or outpatient management is appropriate when ANY of the following applies and no inpatient criterion is met.
Observation or outpatient management
A single brief seizure occurred with return to baseline, therapeutic antiseizure medication was restarted, and there is no new imaging change.
Headache or a mild, stable deficit from known metastases is present without midline shift or hydrocephalus and is improving on oral dexamethasone.
Newly found asymptomatic brain metastases are identified on staging imaging and treatment planning proceeds as an outpatient.
Outpatient stereotactic radiosurgery or fractionated radiation is planned for a neurologically stable member.
Intensive care unit
ICU care is appropriate when ANY of the following is present.
ICU-level criteria
GCS is 8 or less, the member cannot protect the airway, or mechanical ventilation is required.
Clinical or imaging signs of herniation are present, including new pupillary asymmetry, posturing, or basal-cistern effacement, or hyperosmolar therapy is required more often than every 6 hours.
Status epilepticus or seizures require continuous IV anesthetic infusion or continuous EEG.
An external ventricular drain is in place, or the member is within the first 12 to 24 hours after craniotomy.
Step-down or intermediate care
Step-down or intermediate care is appropriate when ANY of the following is present and no ICU criterion is met.
Step-down or intermediate-care criteria
GCS is 9 to 13 and stable, with neurologic checks required every 1 to 2 hours.
The member is post-craniotomy after the initial ICU period, or is post-shunt placement with neurologic checks every 2 hours.
A seizure cluster is controlled but requires IV antiseizure medication titration and close neurologic monitoring.
Medical-surgical unit
Medical-surgical care is appropriate when ANY of the following applies and no higher-level criterion is met.
Medical-surgical criteria
The neurologic examination is stable on IV or oral dexamethasone, with neurologic checks every 4 hours.
The member is awaiting or receiving radiation planning when outpatient travel is unsafe.
Steroid-induced hyperglycemia or another complication requires daily treatment adjustment.
Discharge readiness
Discharge readiness requires ALL of the following.
The neurologic examination is stable or improving for at least 24 hours without hyperosmolar therapy.
There has been no seizure for at least 24 hours on an oral antiseizure regimen.
The member is on an oral corticosteroid regimen with a written taper plan and glucose management.
Swallowing is safe or an alternative nutrition plan is in place, and mobility is safe or a plan is established at the next level of care.
Local therapy is completed or scheduled, including a radiation consultation and simulation date or postoperative imaging and radiation plan, and oncology follow-up is scheduled within 7 to 14 days.
Continued-stay criteria
Continued inpatient stay is medically necessary when reviewed at least every 24 hours and ANY of the following is documented.
Continued-stay triggers
The neurologic examination has not been stable for 24 hours, or GCS is below baseline and changing.
Ongoing hyperosmolar therapy, IV antiseizure medication titration, or an external ventricular drain is required.
Surgery or urgent radiation is scheduled within 72 hours, or postoperative recovery does not yet meet discharge-readiness criteria.
A steroid complication, such as hyperglycemia above 300 mg/dL, gastrointestinal bleeding, or infection, requires inpatient treatment.
Extended-stay review
Days beyond the planning benchmark require an extended-stay trigger, objective evidence, and a targeted plan.
At least one extended-stay trigger
Persistent mass effect or hydrocephalus requires drainage or shunt.
A postoperative complication is present, including hemorrhage, infection, or cerebrospinal fluid leak.
The member cannot swallow or ambulate safely while a placement plan is being made and an active acute need remains.
Objective evidence supporting the documented extended-stay trigger is provided.
A targeted plan addressing the active acute need is documented.
Does not meet criteria
The following scenarios do not meet this policy's medical-necessity criteria and are referred for physician review.
Admission is solely to start dexamethasone or arrange radiation in a neurologically stable member.
Admission is for staging MRI or treatment planning for asymptomatic brain metastases.
Inpatient days are solely to deliver fractionated radiation to a stable member who can travel.
Continued acute stay is solely while awaiting skilled nursing, rehabilitation, hospice, or home-health placement when no acute need remains.
Custodial, respite, or convenience days, including caregiver unavailability or transportation delay, are requested without an acute clinical need.
This policy addresses acute inpatient admission, level-of-care assignment, continued stay, and discharge for adult members with known or newly diagnosed brain or leptomeningeal metastases complicated by symptomatic vasogenic edema, mass effect, hydrocephalus, hemorrhage, or seizures. Elective outpatient stereotactic radiosurgery and whole-brain radiation, primary brain tumors, and inpatient stays for elective craniotomy are reviewed under separate policies; craniotomy MS-DRGs are listed only for routing when resection occurs during the admission.
The following utilization does not meet this policy’s acute inpatient medical-necessity criteria: stable outpatient-appropriate admissions, including admission solely to start dexamethasone, arrange radiation, obtain staging MRI, or perform treatment planning for asymptomatic metastases; inpatient fractionated radiation when the member is stable and able to travel; continued days solely awaiting skilled nursing, rehabilitation, hospice, or home-health placement when no acute need remains; and custodial, respite, convenience, caregiver-unavailability, or transportation-delay days without an acute clinical need. These requests are referred for physician review and discharge planning; previously authorized days are not retroactively denied.
Covered Treatment and Supportive Regimens
Covered service
Clinical indication
Coverage
Surgery, stereotactic radiosurgery, or radiation selected by a multidisciplinary team
Symptomatic brain metastases requiring local therapy
Covered with criteria
Covered service
Clinical indication
Coverage
Corticosteroid treatment, including dexamethasone
Symptomatic vasogenic edema
Covered with criteria
Covered service
Clinical indication
Coverage
IV antiseizure medication, hyperosmolar therapy, airway or continuous EEG support, and neurosurgical intervention as clinically indicated
Seizure, seizure cluster, status epilepticus, or intracranial pressure complication requiring hospital-level care
Covered with criteria
Coding and Utilization Reference
ICD-10-CM metastatic disease of the nervous systemICD-10
C79.31
Secondary malignant neoplasm of brain
C79.32
Secondary malignant neoplasm of cerebral meninges
C79.40
Secondary malignant neoplasm of unspecified part of nervous system
Related complicationsGastrointestinal bleeding or infection requiring inpatient treatment also support continued stay
Authorization, Documentation, and Review Requirements
Note
Medical-Necessity Review
Medical-necessity review evaluates the admission, level of care, continued-stay needs, and discharge criteria. A request that satisfies the applicable criteria may be approved; requests that do not meet criteria are referred for physician review.
Denial Risk
Physician Review for Adverse or Partial Determinations
Automated systems and non-physician clinical reviewers may approve a request in full or in part but may never issue an adverse determination. Only a licensed physician of the same or similar specialty may issue an adverse determination after offering the requesting provider a peer-to-peer discussion; if only part of the request is supported, approve the supported portion and review only the unsupported increment.
The reviewing physician must meet applicable licensure, specialty, and medical-director requirements of the plan's situs state.
The absence of a criterion addressing a service is not, by itself, a basis for an adverse determination; a physician must apply generally accepted standards of medical practice.
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: documentation
Unsupported block type: denial_risk
Unsupported block type: denial_risk
Unsupported block type: denial_risk
Unsupported block type: denial_risk
Unsupported block type: prior_auth
Unsupported block type: denial_risk
Clinical Background
Brain metastases commonly arise from lung cancer, breast cancer, melanoma, and other solid tumors. Symptomatic vasogenic edema is generally treated with corticosteroids, including dexamethasone, while surgery, stereotactic radiosurgery, or radiation is selected by a multidisciplinary team. Inpatient care is generally needed for declining consciousness, progressive neurologic deficits, herniation risk, hydrocephalus, hemorrhage, uncontrolled seizures, or urgent surgery; stable symptoms are often managed with oral dexamethasone and outpatient radiation planning.
Operational Definitions
Mass effect
DefinitionImaging evidence of displacement of brain structures by tumor and edema
Midline findingMidline shift may indicate mass effect
Other imaging findingsSulcal or ventricular effacement, or basal cistern compression
Status epilepticus
DurationA seizure lasting 5 minutes or longer
RecurrenceRecurrent seizures
Neurologic baselineRecurrent seizures occur without return to neurologic baseline between them
Intermediate care
Neurologic checksApproximately every 1 to 2 hours
Organ supportNo need for organ support
Level of careIntermediate or step-down care
ICU care
AirwayAirway protection may be required
MonitoringFrequent neurologic monitoring
Intracranial pressureIntracranial-pressure management may be required
Concurrent review
Review timingReview applies to each continued-stay period
Authorized daysDays already authorized are not retroactively denied
Length of stayExpected length of stay is a planning benchmark, not a limit on covered days